Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Coherus BioSciences Inc is a biotechnology business based in the US. Coherus BioSciences shares (CHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Coherus BioSciences employs 311 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$16.79|
|52-week range||$12.21 - $22.22|
|50-day moving average||$16.73|
|200-day moving average||$14.71|
|Wall St. target price||$26.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.29|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.24%|
|1 month (2021-09-24)||-5.30%|
|3 months (2021-07-23)||28.46%|
|6 months (2021-04-23)||12.76%|
|1 year (2020-10-23)||-4.55%|
|2 years (2019-10-24)||-0.77%|
|3 years (2018-10-24)||54.46%|
|5 years (2016-10-24)||30.69|
Valuing Coherus BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherus BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Coherus BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $159.2 million.
The EBITDA is a measure of a Coherus BioSciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$394.6 million|
|Gross profit TTM||$295.4 million|
|Return on assets TTM||-11.54%|
|Return on equity TTM||-89.4%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
There are currently 7.4 million Coherus BioSciences shares held short by investors – that's known as Coherus BioSciences's "short interest". This figure is 13.4% down from 8.6 million last month.
There are a few different ways that this level of interest in shorting Coherus BioSciences shares can be evaluated.
Coherus BioSciences's "short interest ratio" (SIR) is the quantity of Coherus BioSciences shares currently shorted divided by the average quantity of Coherus BioSciences shares traded daily (recently around 765625.41322314). Coherus BioSciences's SIR currently stands at 9.68. In other words for every 100,000 Coherus BioSciences shares traded daily on the market, roughly 9680 shares are currently held short.
However Coherus BioSciences's short interest can also be evaluated against the total number of Coherus BioSciences shares, or, against the total number of tradable Coherus BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Coherus BioSciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Coherus BioSciences shares in existence, roughly 100 shares are currently held short) or 0.1368% of the tradable shares (for every 100,000 tradable Coherus BioSciences shares, roughly 137 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Coherus BioSciences.
Find out more about how you can short Coherus BioSciences stock.
We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $12.21 up to $22.2166. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 0.972. This would suggest that Coherus BioSciences's shares are less volatile than average (for this exchange).
Coherus BioSciences, Inc. , a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 22, 2021
Everything we know about the Trump Media and Technology Group IPO, plus information on how to buy in.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.